Log in

NYSE:RCUS - Arcus Biosciences Stock Price, Forecast & News

$8.65
-0.29 (-3.24 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$8.56
Now: $8.65
$9.11
50-Day Range
$7.31
MA: $8.14
$9.52
52-Week Range
$6.30
Now: $8.65
$13.66
Volume50,139 shs
Average Volume101,340 shs
Market Capitalization$396.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.03
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone510-694-6200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.35 million
Book Value$5.29 per share

Profitability

Net Income$-49,590,000.00
Net Margins-1,180.37%

Miscellaneous

Employees108
Market Cap$396.69 million
Next Earnings Date3/3/2020 (Estimated)
OptionableOptionable

Receive RCUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.


Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences Inc (NYSE:RCUS) issued its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.51) EPS for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.02. The company had revenue of $1.75 million for the quarter, compared to analyst estimates of $1.34 million. Arcus Biosciences had a negative return on equity of 38.73% and a negative net margin of 1,180.37%. View Arcus Biosciences' Earnings History.

When is Arcus Biosciences' next earnings date?

Arcus Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Arcus Biosciences.

What price target have analysts set for RCUS?

5 Wall Street analysts have issued 12-month price targets for Arcus Biosciences' shares. Their forecasts range from $15.00 to $22.00. On average, they expect Arcus Biosciences' share price to reach $19.25 in the next twelve months. This suggests a possible upside of 122.5% from the stock's current price. View Analyst Price Targets for Arcus Biosciences.

What is the consensus analysts' recommendation for Arcus Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcus Biosciences.

Has Arcus Biosciences been receiving favorable news coverage?

News coverage about RCUS stock has been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arcus Biosciences earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Arcus Biosciences.

Are investors shorting Arcus Biosciences?

Arcus Biosciences saw a drop in short interest in the month of November. As of November 29th, there was short interest totalling 1,390,000 shares, a drop of 12.0% from the November 14th total of 1,580,000 shares. Based on an average trading volume of 231,500 shares, the short-interest ratio is presently 6.0 days. Currently, 5.5% of the shares of the company are sold short. View Arcus Biosciences' Current Options Chain.

Who are some of Arcus Biosciences' key competitors?

What other stocks do shareholders of Arcus Biosciences own?

Who are Arcus Biosciences' key executives?

Arcus Biosciences' management team includes the folowing people:
  • Dr. Terry Rosen Ph.D., Co-Founder, Chairman & CEO (Age 59)
  • Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 61)
  • Mr. Steven Chan, Consultant (Age 47)
  • Ms. Rekha Hemrajani, Chief Operating & Financial Officer (Age 49)
  • Dr. Stephen Young Ph.D., VP of Technology (Age 50)

When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (1.35%), Millennium Management LLC (0.41%), Parallel Advisors LLC (0.19%), California State Teachers Retirement System (0.11%), Rhumbline Advisers (0.11%) and Barclays PLC (0.05%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Institutional Ownership Trends for Arcus Biosciences.

Which major investors are selling Arcus Biosciences stock?

RCUS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC and Bailard Inc.. View Insider Buying and Selling for Arcus Biosciences.

Which major investors are buying Arcus Biosciences stock?

RCUS stock was acquired by a variety of institutional investors in the last quarter, including Parallel Advisors LLC, Millennium Management LLC, State Street Corp, California Public Employees Retirement System, Russell Investments Group Ltd., Rhumbline Advisers, Meeder Asset Management Inc. and California State Teachers Retirement System. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Insider Buying and Selling for Arcus Biosciences.

How do I buy shares of Arcus Biosciences?

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $8.65.

How big of a company is Arcus Biosciences?

Arcus Biosciences has a market capitalization of $396.69 million and generates $8.35 million in revenue each year. The company earns $-49,590,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe.View Additional Information About Arcus Biosciences.

What is Arcus Biosciences' official website?

The official website for Arcus Biosciences is http://www.arcusbio.com/.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]


MarketBeat Community Rating for Arcus Biosciences (NYSE RCUS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  214
MarketBeat's community ratings are surveys of what our community members think about Arcus Biosciences and other stocks. Vote "Outperform" if you believe RCUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel